Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

2 results about "Paliperidone" patented technology

This medication is used to treat certain mental/mood disorders (such as schizophrenia, schizoaffective disorder).

A paliperidone therapeutic effect prediction method and system based on plasma metabolomics

ActiveCN120853799BBaseline dataMetabolite
The present application relates to the field of medical informatics, and provides a paliperidone efficacy prediction method and system based on plasma metabolomics. The method comprises the following steps: collecting basic data of a target patient; performing feature selection on metabolites through the basic data to obtain relevant metabolites corresponding to paliperidone efficacy; training a neural network based on the relevant metabolites and baseline data in the basic data to obtain a prediction model; and performing paliperidone efficacy prediction on a patient to be predicted through the prediction model to obtain a prediction result. The present application can predict the probability of patient response to paliperidone, thereby more accurately evaluating the efficacy of paliperidone before medication, and providing an auxiliary decision for individualized medication.
Owner:INSTITUTE OF MENTAL HEALTH OF PEKING UNIVERSITY (SIXTH HOSPITAL OF PEKING UNIVERSITY)

SNP site detection primer probe combination for guiding individualized medication of second-generation antipsychotic drugs and application thereof

PendingCN122357713AQuetiapineGenetics
This invention belongs to the field of SNP site detection technology for guiding the use of second-generation antipsychotic drugs. Specifically, it relates to primer and probe combinations and applications for SNP site detection to guide personalized medication of second-generation antipsychotic drugs. The SNP site is rs17782313. The primer and probe combination includes an upstream primer SEQ ID NO:1 that specifically amplifies the wild-type T allele, an upstream primer SEQ ID NO:2 that specifically amplifies the mutant C allele, a universal downstream primer SEQ ID NO:3, a wild-type probe SEQ ID NO:4, and a mutant probe SEQ ID NO:5. This invention assesses the genetic risk of weight gain and metabolic disorders in patients with mental illness after taking second-generation antipsychotic drugs such as risperidone, quetiapine, amisulpride, and paliperidone through rapid and accurate genotyping. It features high specificity, high accuracy, speed, simplicity, and controllable cost, and can achieve rapid single-tube genotyping, providing key genetic evidence for the clinical development of personalized medication regimens.
Owner:CHONGQING PUJI LIFE TECH CO LTD